Venus Remedies Ltd

Venus Remedies will hold a meeting of the Board of Directors of the Company on 26 May 2025.Powered by Capital Market - Live

The drug is intended for the treatment of bloodstream infections caused by polymyxin B (PMB)-susceptible strains in adults. Developed by the Venus Medicine Research Centre (VMRC)'the R&D arm of Venus Remedies'VRP-034 is a novel supramolecular cationic (SMC) formulation of polymyxin B sulphate. It has been designed specifically to mitigate the nephrotoxic effects often associated with conventional polymyxin B therapy, a critical concern in treating drug-resistant infections. The QIDP status has been granted under the Generating Antibiotic Incentives Now (GAIN) Act, a U.S. initiative aimed at encouraging the development of new antibiotics to combat serious or life-threatening infections. With this designation, VRP-034 now qualifies for several key regulatory benefits, including priority review, eligibility for fast track designation, and an additional five years of market exclusivity upon receiving FDA approval. Polymyxins like PMB and colistin are critical last-resort antibiotics for treating multidrug-resistant (MDR) infections but are often limited by high rates of nephrotoxicity, affecting up to 60% of patients. Venus Remedies' investigational product, VRP-034, aims to overcome this limitation by maintaining the therapeutic profile of PMB while significantly reducing kidney toxicity'by up to 70%'as shown in preclinical studies. It has demonstrated strong efficacy against resistant pathogens and a favorable safety profile using advanced testing models. The recent QIDP designation by the US FDA highlights the drug's potential and reinforces the company's focus on tackling antimicrobial resistance. Venus Remedies is a pharmaceutical company specializing in critical care injectables. It reported a consolidated net profit surged 186.13% to Rs 19.60 crore on a 23.31% increase in revenue from operations to Rs 176.85 crore in Q3 FY25 over Q3 FY24. Powered by Capital Market - Live

MET-X, a metallo-beta-lactamase (MBL) inhibitor, targets drug-resistant Gram-negative bacteria, a significant concern in India due to high meropenem resistance. Venus Remedies will initiate Phase I trials in India, testing MET-X with meropenem, progressing to Phase II/III trials for drug-resistant complicated urinary tract infections (cUTIs). The company's established expertise in meropenem marketing and manufacturing is crucial for this development. MET-X's broad-spectrum action combats Gram-negative bacteria that resist beta-lactam antibiotics, offering a solution to antibiotic resistance. Clinical trials in India will adhere to international standards (FDA, EMA, MHRA), facilitating global commercialization. The agreement also allows for potential expansion to other MET-X combinations. Venus Remedies is an Indian research-driven pharmaceutical company dedicated to developing innovative solutions to improve patient outcomes. Venus Remedies reported a consolidated net profit surged 186.13% to Rs 19.60 crore on a 23.31% increase in revenue from operations to Rs 176.85 crore in Q3 FY25 over Q3 FY24. Powered by Capital Market - Live

Stallion India Fluorochemicals Ltd, Bliss GVS Pharma Ltd, BEML Land Assets Ltd and Repro India Ltd are among the other gainers in the BSE's 'B' group today, 05 February 2025.Venus Remedies Ltd surged 20.00% to Rs 348.6 at 12:03 IST. The stock was the biggest gainer in the BSE's 'B' group. On the BSE, 7966 shares were traded on the counter so far as against the average daily volumes of 2333 shares in the past one month. Stallion India Fluorochemicals Ltd spiked 14.14% to Rs 107.78. The stock was the second biggest gainer in 'B' group. On the BSE, 5.49 lakh shares were traded on the counter so far as against the average daily volumes of 2.75 lakh shares in the past one month. Bliss GVS Pharma Ltd soared 13.65% to Rs 159. The stock was the third biggest gainer in 'B' group. On the BSE, 1.47 lakh shares were traded on the counter so far as against the average daily volumes of 67230 shares in the past one month. BEML Land Assets Ltd exploded 13.45% to Rs 236.15. The stock was the fourth biggest gainer in 'B' group. On the BSE, 50714 shares were traded on the counter so far as against the average daily volumes of 4522 shares in the past one month. Repro India Ltd advanced 11.58% to Rs 560. The stock was the fifth biggest gainer in 'B' group. On the BSE, 4269 shares were traded on the counter so far as against the average daily volumes of 3197 shares in the past one month. Powered by Capital Market - Live

Profit before exceptional items and tax in Q3 FY25 was at Rs 14.97 crore, up 92.42% from Rs 7.78 crore recorded in Q3 FY24. Exceptional profit stood at Rs 9.91 crore in Q3 FY25. Total expenses advanced 18.79% YoY to Rs 163.92 crore in Q3 FY23. The cost of materials consumed was at Rs 97.52 crore (up 11.69% YoY), while employee benefits expenses stood at Rs 19.55 crore (up 12.68% YoY) during the December 2024 quarter. During Q3 FY25, EBIDTA stood at Rs 20.39 crore, up 41.7% from Rs 14.39 crore posted in corresponding quarter last year. On a nine-month basis, the company's net profit jumped 35.45% to Rs 24.34 crore on 11.48% rise in revenue from operations to Rs 452.92 crore in 9M FY24 over 9M FY23. Venus Remedies is among the 10 leading fixed-dose injectable manufacturers in the world. Powered by Capital Market - Live

Net profit of Venus Remedies rose 186.13% to Rs 19.60 crore in the quarter ended December 2024 as against Rs 6.85 crore during the previous quarter ended December 2023. Sales rose 23.32% to Rs 176.86 crore in the quarter ended December 2024 as against Rs 143.42 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales176.86143.42 23 OPM %10.388.39 - PBDT20.3814.32 42 PBT14.977.78 92 NP19.606.85 186 Powered by Capital Market - Live

Venus Remedies will hold a meeting of the Board of Directors of the Company on 4 February 2025.Powered by Capital Market - Live

The company's manufacturing facility covers, Cephalosporin, Carbapenem and Oncology (liquid& lyophilized injectable) formulations. The company had received its first EU GMP certification in 2007. It has consistently maintained a robust presence in the European market for over 15 years. As one of the leading exporters of Meropenem outside India and with multiple marketing aithoriszations across Europe. Venus Remedies is a global pharmaceutical company with a strong focus on fixed dosage injectables. It has a wide range of products and is present in many countries around the world. The company is also committed to research and innovation. The company's consolidated net profit declined 64.7% YoY to Rs 3.51 crore in Q2 FY25. Net sales fell marginally 0.2% to Rs 167.45 crore in Q2 FY25 as compared with Rs 167.72 crore in Q2 FY24. Powered by Capital Market - Live

The key equity indices traded with minor losses in mid-afternoon trade. The Nifty traded below the 23,650 mark after hitting the day's high of 23,689.85 in mid-afternoon trade. Oil & gas shares advanced after declining in the past two consecutive trading sessions. At 14:30 IST, the barometer index, the S&P BSE Sensex, declined 131.29 points or 0.17% to 78,116.84. The Nifty 50 index shed 10.50 points or 0.04% to 23,634.40. The broader market outperformed the benchmark indices. The S&P BSE Mid-Cap index rose 0.15% and the S&P BSE Small-Cap index advanced 0.52%. The market breadth was positive. On the BSE, 2,114 shares rose and 1,796 shares fell. A total of 127 shares were unchanged. Buzzing Index: The Nifty Oil & Gas index gained 1.19% to 10,757.90. The index fell 0.83% in past two consecutive trading sessions. Oil India (up 3.17%), Oil & Natural Gas Corpn (up 2.75%), Mahanagar Gas (up 2.41%), Indraprastha Gas (up 2.06%), Castrol India (up 1.89%), Indian Oil Corporation (up 1.59%), GAIL (India) (up 1.53%), Aegis Logistics (up 1%), Petronet LNG (up 0.99%) and Hindustan Petroleum Corporation (up 0.81%) advanced. On the other hand, Adani Total Gas (down 2.62%), Gujarat Gas (down 0.53%) and Gujarat State Petronet (down 0.51%) edged lower. Numbers to Track: The yield on India's 10-year benchmark federal paper slipped 0.17% to 6.874 as compared with the previous close of 6.886. In the foreign exchange market, the rupee edged lower against the dollar. The partially convertible rupee was hovering at 85.6000, compared with its close of 85.5250 during the previous trading session. MCX Gold futures for the 5 February 2025 settlement rose 0.36% to Rs 76,535. The US Dollar index (DXY), which tracks the greenback's value against a basket of currencies, was down 0.19% to 107.92. The United States 10-year bond yield declined 0.68% to 4.514. In the commodities market, Brent crude for February 2025 settlement added 54 cents, or 0.73% to $74.53 a barrel. Stocks in Spotlight: Venus Remedies jumped 4.61% after the company received good manufacturing practice (GMP) certification from Ministry of Health of Moldova for the company's antibiotic -Carbapenem facility. Shares of Adani Wilmar dropped 6.69% and Adani Enterprises (AEL) declined 2.61% after AEL informed that it has signed an agreement with Wilmar International to exit from the joint venture (JV), Adani Wilmar.Powered by Capital Market - Live

The company said that it is well-positioned to further extend its presence in the eastern European market ensuring access to high quality, effective, and reliable antibiotics for healthcare providers and patients across the region. Venus Remedies is a global pharmaceutical company with a strong focus on fixed dosage injectables. It has a wide range of products and is present in many countries around the world. The company is also committed to research and innovation. The company's consolidated net profit declined 64.7% YoY to Rs 3.51 crore in Q2 FY25. Net sales fell marginally 0.2% to Rs 167.45 crore in Q2 FY25 as compared with Rs 167.72 crore in Q2 FY24. Powered by Capital Market - Live